CV · CapsoVision Inc. Common Stock
View on chartInsiders & Stakes
| Shen Ching Hang 10% Owner | ▲ Buy | Open Market | 2,926,655 Shares held | 9/15/2026 | View profile |
| Eliyahou Harari, et al. 10% Owner | ▲ Buy | Open Market | 878,734 Shares held | 9/18/2026 | View profile |
| Kang-Huai Wang See Remarks | ▼ Sell | Other | 721,732 Shares held | 7/3/2025 | View profile |
| Douglas Patrick Atkinson Head of Global Sales | ▲ Buy | Option Exercise | 107,357 Shares held | 5/5/2026 | View profile |
| Michele Harari Director | ▲ Buy | Option Exercise | 61,065 Shares held | 6/30/2026 | View profile |
| Wen-Herng Henry King | ▲ Buy | Option Exercise | 25,619 Shares held | 6/30/2026 | View profile |
| Rebecca Ann Petersen Director of Clinical Affairs | ▲ Buy | Option Exercise | 24,834 Shares held | 8/18/2025 | View profile |
| Hui Ying Kuo | ▲ Buy | Option Exercise | 15,263 Shares held | 6/30/2026 | View profile |
| Chen Lung Tsai | ▲ Buy | Option Exercise | 4,929 Shares held | 6/30/2026 | View profile |
| Julia S. Gouw Director | ▲ Buy | Option Exercise | 4,909 Shares held | 6/30/2026 | View profile |
| Joanne Carol Imperial Director | ▲ Buy | Option Exercise | 3,709 Shares held | 6/30/2026 | View profile |
Transaction History
| Eliyahou Harari, et al. | ▲ Buy | Open Market | 878,735 | $5.0M | 9/18/2026 |
| Eliyahou Harari, et al. | ▲ Buy | Open Market | 878,734 | $5.0M | 9/18/2026 |
| Shen Ching Hang | ▲ Buy | Open Market | 878,734 | $5.0M | 9/15/2026 |
| Eliyahou Harari, et al. | ▲ Buy | Open Market | 61,068 | $411K | 7/17/2026 |
| Eliyahou Harari, et al. | ▲ Buy | Open Market | 81,300 | $495K | 7/8/2026 |
| Joanne Carol Imperial | ▲ Buy | Option Exercise | 2,022 | $15K | 6/30/2026 |
| Chen Lung Tsai | ▲ Buy | Option Exercise | 2,022 | $15K | 6/30/2026 |
| Hui Ying Kuo | ▲ Buy | Option Exercise | 2,022 | $15K | 6/30/2026 |
| Wen-Herng Henry King | ▲ Buy | Option Exercise | 2,022 | $15K | 6/30/2026 |
| Michele Harari | ▲ Buy | Option Exercise | 2,022 | $15K | 6/30/2026 |
| Julia S. Gouw | ▲ Buy | Option Exercise | 2,022 | $15K | 6/30/2026 |
| Eliyahou Harari, et al. | ▲ Buy | Open Market | 13,850 | $102K | 6/26/2026 |
| Douglas Patrick Atkinson | ▲ Buy | Option Exercise | 34,786 | $20K | 5/5/2026 |
| Douglas Patrick Atkinson | ▲ Buy | Option Exercise | 36,036 | $10K | 5/4/2026 |
| Douglas Patrick Atkinson | ▲ Buy | Option Exercise | 30,030 | $11K | 5/4/2026 |
| Douglas Patrick Atkinson | ▲ Buy | Option Exercise | 6,505 | $4K | 5/4/2026 |
| Michele Harari | ▲ Buy | Option Exercise | 2,887 | $31K | 12/31/2025 |
| Julia S. Gouw | ▲ Buy | Option Exercise | 2,887 | $31K | 12/31/2025 |
| Joanne Carol Imperial | ▲ Buy | Option Exercise | 2,887 | $31K | 12/31/2025 |
| Wen-Herng Henry King | ▲ Buy | Option Exercise | 2,887 | $31K | 12/31/2025 |
| Hui Ying Kuo | ▲ Buy | Option Exercise | 2,887 | $31K | 12/31/2025 |
| Chen Lung Tsai | ▲ Buy | Option Exercise | 2,887 | $31K | 12/31/2025 |
| Rebecca Ann Petersen | ▲ Buy | Option Exercise | 24,834 | $9K | 8/18/2025 |
| Eliyahou Harari, et al. | ▼ Sell | Other | 3,186,904 | — | 7/3/2025 |
| Eliyahou Harari, et al. | ▼ Sell | Other | 517,759 | — | 7/3/2025 |
| Eliyahou Harari, et al. | ▼ Sell | Other | 517,759 | — | 7/3/2025 |
| Wen-Herng Henry King | ▼ Sell | Other | 20,710 | — | 7/3/2025 |
| Hui Ying Kuo | ▼ Sell | Other | 10,354 | — | 7/3/2025 |
| Chen Lung Tsai | ▼ Sell | Other | 91,432 | — | 7/3/2025 |
| Kang-Huai Wang | ▼ Sell | Other | 446,896 | — | 7/3/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CapsoVision Receives FDA Clearance for AI Highlights Tool
CapsoVision has secured FDA clearance for its AI Highlights reading tool on the CapsoCam Plus system. The approval allows the company to market the feature as a medical device, potentially expanding its use in clinical settings. The clearance may enhance the product’s value proposition and support future growth.
CapsoVision Receives FDA Clearance for AI Highlights Tool. CapsoVision has secured FDA clearance for its AI Highlights reading tool on the CapsoCam Plus system. The approval allows the company to market the feature as a medical device, potentially expanding its use in clinical settings. The clearance may enhance the product’s value proposition and support future growth.